« — Four-year mean follow-up data demonstrate an overall response rate (ORR) of over 80% throughout the follow-up period —
— Randomized, double-blind Phase 3 study to assess the efficacy and safety of GIVinostat versus hydroxyurea IN JAK2V617F-positive high-risk Polycythemia Vera patients (GIV-IN PV TRIAL) with over 100 participating international clinical sites to be initiated by mid-2021 —«
Thanks for sharing.
Polycythemia Vera Management Often Does Not Follow GuidelinesThrombotic Events in Patients With Polycythemia Vera and Essential Thrombocythemia Outcomes of JAK2 V617F-positive polycythemia vera and ET according to the JAK2 V617F allele burden
Long Term Hydrea patients?The Gut Microbiota in Patients with Polycythemia Vera is Distinct from that of Healthy Controls and Varies by Treatment
